Hepatitis B Pipeline Drugs Assessment
Hepatitis B Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018
Hepatitis B is the viral infection that attacks liver and caused by hepatitis B virus. Hepatitis B virus may infect for a short time and causes acute infection or may stay longer periods, causes chronic hepatitis B. Usually symptoms may not appear, eventually may lead to flue and it spreads to other parts of the body. Disease may spread from one to another through blood and body fluids.
According to World Health Organization (WHO), in 2015, there were 257 million people are living with hepatitis B, in which most of the patients diagnosed have already advanced liver disease.
Hepatitis B diagnosed with the blood test, if the infection damages the liver, liver biopsy may be suggested for the patient. Furthermore, vaccines are available for prevention of disease. There is no specific treatment available for hepatitis B. Currently available treatments are aimed to reduce the disease symptoms and slows the further worsening of the disease. Chronic hepatitis B is generally treated with the available antiviral drugs to slow down the progression of cirrhosis and reduce the chances of liver cancer.
By Mechanism, hepatitis B pipeline drugs market is segmented into
- Direct Acting (Targets Virus)
- Indirectly Acting (Target Host)
By trial phase, hepatitis B pipeline drugs are segmented into
- Preclinical Studies
By company, hepatitis B are assessment is segmented into
- Gilead Sciences, Inc. (U.S.)
- Arbutus Biopharma Corporation (Canada)
- Alnylam Pharmaceuticals (U.S.)
- Benitec Biopharma Ltd (Australia)
- ContraVir Pharmaceuticals (U.S.)
- Hoffmann-La Roche AG (Switzerland)
- Hepatera LLC (Russia)
Currently, more than 30 drugs are being developed for the treatment of hepatitis B virus. Many of the companies are focused on the development of directly acting hepatitis B drugs which acts on various life stages of virus. Furthermore, most of the direct acting drugs are RNAi agents, which causes the destruction of virus. In addition, indirectly acting drug classes include, therapeutic vaccines, innate immune system activators, and programmed cell death inducers.
- In November 2017, Hepatera LLC and its developmental partner MYR GmbH announced positive results from phase 2b clinical trials of its developmental chronic hepatitis B with delta-agent (hepatitis D), Myrcludex B. Claimed that Myrcludex B demonstrated good safety profile throughout a 24 week period and during the study there was no serious events or early termination to the study drug.
Hepatitis B Pipeline Drugs Assessment report studies the various therapeutics under clinical development for hepatitis B treatment along with targets for a various drug candidate. The report provides a plethora of information pertaining to trail phases, companies involved in the hepatitis B pipeline drugs development. This report studies the dynamics of the Hepatitis B Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on hepatitis B pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.
Key Features of the Report:
- Provides the information related to universities and research institutes working in the therapeutics development
- The report comprehensively covers the all active and discontinued studies
- Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
- Presents the prominent targets for drug development in each stage of clinical trial
- Provides the in-depth analysis of each drug candidates in the clinical trial phases